NCT04591262View on ClinicalTrials.gov

A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

January 28, 2021

Study Completion Date

January 28, 2021

Conditions
Healthy
Interventions
DRUG

14C-PF-06826647-LR 600 mg PO

14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep

DRUG

PF-06826647 600 mg PO

Unlabeled PF-06826647 600 mg

DRUG

14C-PF-06826647 100 ug IV

14C-PF-06826647 100 ug IV

Trial Locations (2)

9728 NZ

PRA Health Sciences, Groningen

3584 BL

PRA Health Sciences Utrecht, Utrecht

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04591262 - A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants | Biotech Hunter | Biotech Hunter